R428, a Selective Small Molecule Inhibitor of Axl Kinase, Blocks Tumor Spread and Prolongs Survival in Models of Metastatic Breast Cancer

被引：423

作者：

Holland, Sacha J. ^{[1
]}

Pan, Alison ^{[1
]}

Franci, Christian ^{[1
]}

Hu, Yuanming ^{[1
]}

Chang, Betty ^{[1
]}

Li, Weiqun ^{[1
]}

Duan, Matt ^{[1
]}

Torneros, Allan ^{[1
]}

Yu, Jiaxin ^{[1
]}

Heckrodt, Thilo J. ^{[1
]}

Zhang, Jing ^{[1
]}

Ding, Pingyu ^{[1
]}

Apatira, Ayodele ^{[1
]}

Chua, Joanne ^{[2
]}

Brandt, Ralf ^{[2
]}

Pine, Polly ^{[1
]}

Goff, Dane ^{[1
]}

Singh, Rajinder ^{[1
]}

Payan, Donald G. ^{[1
]}

Hitoshi, Yasumichi ^{[1
]}

机构：

[1] Rigel Inc, San Francisco, CA 94112 USA

[2] VivoPharm Pty Ltd, Adelaide, SA, Australia

来源：

CANCER RESEARCH | 2010年 / 70卷 / 04期

关键词：

RECEPTOR TYROSINE KINASE; ACUTE MYELOID-LEUKEMIA; MAMMARY-CARCINOMA; 4T1; DRUG-RESISTANCE; GROWTH-ARREST; IN-VIVO; CELLS; ACTIVATION; INVASION; PROGRESSION;

D O I：

10.1158/0008-5472.CAN-09-2997

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Accumulating evidence suggests important roles for the receptor tyrosine kinase Axl in cancer progression, invasion, metastasis, drug resistance, and patient mortality, highlighting Axl as an attractive target for therapeutic development. We have generated and characterized a potent and selective small-molecule inhibitor, R428, that blocks the catalytic and procancerous activities of Axl. R428 inhibits Axl with low nano-molar activity and blocked Axl-dependent events, including Akt phosphorylation, breast cancer cell invasion, and proinflammatory cytokine production. Pharmacologic investigations revealed favorable exposure after oral administration such that R428-treated tumors displayed a dose-dependent reduction in expression of the cytokine granulocyte macrophage colony-stimulating factor and the epithelial-mesenchymal transition transcriptional regulator Snail. In support of an earlier study, R428 inhibited angiogenesis in corneal micropocket and tumor models. R428 administration reduced metastatic burden and extended survival in MDA-MB-231 intracardiac and 4T1 orthotopic (median survival, >80 days compared with 52 days; P < 0.05) mouse models of breast cancer metastasis. Additionally, R428 synergized with cisplatin to enhance suppression of liver micrometastasis. Our results show that Axl signaling regulates breast cancer metastasis at multiple levels in tumor cells and tumor stromal cells and that selective Axl blockade confers therapeutic value in prolonging survival of animals bearing metastatic tumors. Cancer Res; 70(4); 1544-54. (C) 2010 AACR.

引用

页码：1544 / 1554

页数：11

共 42 条

[1]

ASLAKSON CJ, 1992, CANCER RES, V52, P1399

[2] Phosphoproteomic analysis of Her2/neu signaling and inhibition [J].